Assessment

The prediction is about a structural transformation of industrial production over the course of the 21st century: that large, programmable bioreactor 'printers' (fermentation‑tank systems reprogrammed via genetic software to make different products) will replace many single‑purpose factories. That horizon runs to 2100, so as of 2025 only about a quarter of the century has elapsed.

What we see so far (2020–2025)

• Governments now explicitly frame biotechnology and biomanufacturing as a way to make 'almost anything that we use in our day-to-day lives' via programmed microbes, and cite analyses that bioengineering could account for more than a third of global manufacturing output before 2030, indicating serious expectations of a bio‑based manufacturing shift. (bidenwhitehouse.archives.gov)
• The U.S. National Biotechnology and Biomanufacturing Initiative and related executive orders are investing billions to expand domestic biomanufacturing infrastructure and capacity across chemicals, materials, fuels, and health products, which is directionally consistent with the forecast but far from its end-state. (content.govdelivery.com)
• Companies like Ginkgo Bioworks operate 'organism engineering' platforms that genetically program microbes for many industrial applications, explicitly positioning biology as a general manufacturing technology rather than one‑off processes. (en.wikipedia.org)
• In biopharma, single‑use and modular bioreactors are now widely adopted; they reduce cleaning/validation times and are popular because facilities can quickly switch from manufacturing one drug product to another, showing real but still sector‑limited movement toward flexible, multi‑product bioreactor plants. (en.wikipedia.org)

Why the result is inconclusive

• The claim is about an economy‑wide replatforming of industrial production by 2100, not about a short‑term milestone. Existing evidence shows early, sector‑specific progress (especially in drugs and specialty chemicals) and strong policy and commercial interest, but conventional factories overwhelmingly still dominate global manufacturing.
• Nothing observed by late 2025 decisively confirms that most industrial production will move to such programmable bioreactor 'printers', nor does anything make that outcome clearly impossible.

Given the long time horizon and the fact that current developments are only early, partial signals, this prediction cannot yet be judged right or wrong; it remains inconclusive (too early to tell).